🔴 Viking Therapeutics is trading 5% down today amid biotech-sector weakness

Viking Therapeutics is trading at $26.04 (-4.86%) amid biotech-sector pressure and broader-market weakness.

• Biotech ETF XBI is down 2.06%.
• No negative company-specific announcement explaining the decline was found. Recent coverage instead points to positive analyst actions, including a Barclays upgrade and UBS Buy rating.
• The oral VK2735 Phase 3 program was announced recently. The decline may reflect sector sentiment, but available evidence does not establish a direct cause.